Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

European clinicians outline patient treatments using Varian's RapidArc IMRT system

Varian : 17 September, 2008  (Company News)
Clinicians from the first three European hospitals to start clinical treatments using RapidArc - VU University medical centre in Amsterdam, Netherlands, Rigshospitalet in Copenhagen, Denmark and the Oncology Institute of Southern Switzerland in Bellinzona, Switzerland - addressed a packed Emerging Technologies Symposium at the annual ESTRO conference to give detailed accounts of early patient treatments.
Dr Ben Slotman of VU University medical center presented the results of RapidArc treatments in head and neck tumour, lung tumour, brain tumour and brain metastases patients, concluding, 'RapidArc clearly offers fast treatment planning and fast delivery, which means less patient and tumour motion, a more comfortable experience for the patient and the ability to treat more patients each day.'

Dr Slotman said early treatments demonstrated that planning results were at least equivalent to conventional intensity modulated Radiotherapy (IMRT) results and sometimes better, that the planned dose corresponds well to the delivered dose and treatment delivery is often under two minutes. He also described the use of RapidArc as an attractive alternative for 'conventional' stereotactic Radiotherapy for tumours in the brain and lung, mainly because of the significantly shorter delivery times for these high doses.

Luca Cozzi, PD, of the Oncology Institute of Southern Switzerland, outlined the results of his research into the RapidArc QA and verification process, again revealing it compares favourably to those of conventional IMRT. 'We were impressed to see how precisely the delivery can be matched to expected calculations,' said Dr Cozzi. 'Our pre-treatment quality assurance findings confirmed that RapidArc can be delivered with even better agreement to plans than we were used to with IMRT.'

Dr Svend-Aage Engelholm of Rigshospitalet reported the results of a RapidArc programme on prostate cancer patients. 'Both RapidArc and IMRT plans were calculated for sixteen patients and RapidArc was only offered to those patients where a better dose distribution was observed,' said Dr Engelholm. 'Fifteen of them received RapidArc and the treatment delivery time was less than a minute and a half in each case.'

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo